ImpactRx And Majestic Research Announce Innovative Research Partnership
MOUNT LAUREL, N.J., and NEW YORK, Feb. 11 /PRNewswire-FirstCall/ -- ImpactRx, Inc., provider of market insight to the pharmaceutical industry, and Majestic Research Corp, supplier of unbiased, data-driven investment research, today announced the formation of an exclusive partnership benefiting health care investors.
ImpactRx electronically captures promotion and prescribing data on a daily basis from its networks of the nation's highest-prescribing primary care and specialist physicians. Through this unique partnership, Majestic will apply its analytical and custom research capabilities to ImpactRx's data to provide investors with the most timely, accurate and sensitive evaluation of the pharmaceutical market landscape and individual company performance.
"ImpactRx's data combined with Majestic's analytics and insight will provide investors with an unparalleled perspective on marketplace activities," stated Nancy Lurker, CEO and President of ImpactRx. "This enhanced research will enable investors to more accurately evaluate a company's effectiveness at leveraging its commercial opportunities, which is especially important as the difficulty of bringing new compounds through the R&D pipeline continues to increase."
"We are excited to join forces with ImpactRx, whose data provides advanced visibility into market changes and insight that goes well beyond traditional dispensed prescription data," said Tony Berkman, Majestic co-Founder and Director of Research. "Our research expertise combined with ImpactRx's data will offer investors a never before seen view into whether the science translates into commercial success."
About ImpactRx
Founded in October 2000, ImpactRx's physician network is the source of an unprecedented intelligence capability for tracking the promotional initiatives of the pharmaceutical industry and determining their impact on physician behavior. Based in Mount Laurel, New Jersey, ImpactRx is a private company with investment financing provided by Mediphase Venture Partners (http://www.mediphaseventure.com/), Oxford Bioscience Partners (http://www.oxbio.com/), Merck Capital Ventures (http://www.merckcapitalventures.com/) and 3i (http://www.3i.com/). For more information about ImpactRx, please visit http://www.impactrx.com/.
About Majestic Research
Founded in October 2002, Majestic is rapidly establishing itself among institutional investors as the source for a new kind of unbiased, data-driven investment research. Majestic offers its clients a unique research model that takes full advantage of proprietary data sources, technologies and analytical methodologies. In addition to health, Majestic covers numerous other industries with proprietary sources of statistically significant data in: Internet retail, video games, technology hardware, traditional media, casino gaming, auto retail, and homebuilders. For more information about Majestic please visit http://www.majesticresearch.com/.
CONTACT: Patrick Angelastro Vice President, Strategic Development ImpactRx, Inc. 856-273-0221, ext. 102 pangelastro@impactrx.com Jon Steinberg Director, Business Development Majestic Research LLC 646-442-6974 jon@majesticresearch.com
ImpactRx, Inc. and Majestic Research Corp.CONTACT: Patrick Angelastro, Vice President, Strategic Development,ImpactRx, Inc., +1-856-273-0221, ext. 102, pangelastro@impactrx.com; or JonSteinberg, Director, Business Development, Majestic Research LLC,+1-646-442-6974, jon@majesticresearch.com